99.75
price up icon1.51%   1.48
after-market After Hours: 99.57 -0.18 -0.18%
loading
Biontech Se Adr stock is traded at $99.75, with a volume of 661.09K. It is up +1.51% in the last 24 hours and down -10.04% over the past month. BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
See More
Previous Close:
$98.27
Open:
$97.98
24h Volume:
661.09K
Relative Volume:
0.78
Market Cap:
$23.98B
Revenue:
$3.13B
Net Income/Loss:
$-381.72M
P/E Ratio:
-62.18
EPS:
-1.6042
Net Cash Flow:
$-2.15B
1W Performance:
+1.63%
1M Performance:
-10.04%
6M Performance:
-0.88%
1Y Performance:
-15.80%
1-Day Range:
Value
$97.96
$99.98
1-Week Range:
Value
$95.34
$99.98
52-Week Range:
Value
$81.20
$129.27

Biontech Se Adr Stock (BNTX) Company Profile

Name
Name
Biontech Se Adr
Name
Phone
-
Name
Address
-
Name
Employee
6,772
Name
Twitter
@BioNTech_Group
Name
Next Earnings Date
2025-03-10
Name
Latest SEC Filings
Name
BNTX's Discussions on Twitter

Compare BNTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BNTX
Biontech Se Adr
99.75 23.62B 3.13B -381.72M -2.15B -1.6042
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
376.62 97.36B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
576.98 60.19B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
458.37 59.56B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
729.76 44.94B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
329.84 36.14B 3.81B -644.79M -669.77M -6.24

Biontech Se Adr Stock (BNTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-05-25 Reiterated H.C. Wainwright Buy
May-29-25 Initiated Goldman Neutral
Mar-13-25 Initiated Citigroup Buy
Jan-10-25 Initiated Truist Buy
Dec-11-24 Initiated Wells Fargo Overweight
Dec-02-24 Reiterated BMO Capital Markets Outperform
Nov-19-24 Initiated Berenberg Buy
Nov-19-24 Upgrade Evercore ISI In-line → Outperform
Nov-08-24 Upgrade Goldman Neutral → Buy
Sep-24-24 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-17-24 Upgrade Jefferies Hold → Buy
Sep-16-24 Upgrade JP Morgan Underweight → Neutral
Aug-07-24 Upgrade Deutsche Bank Hold → Buy
Aug-02-24 Upgrade HSBC Securities Hold → Buy
May-14-24 Initiated Evercore ISI In-line
Feb-23-24 Initiated BMO Capital Markets Outperform
Jan-05-24 Initiated Oppenheimer Perform
Dec-01-23 Downgrade JP Morgan Neutral → Underweight
Oct-16-23 Downgrade HSBC Securities Buy → Hold
Jul-14-23 Initiated HSBC Securities Buy
May-17-23 Upgrade Redburn Neutral → Buy
Dec-15-22 Upgrade BofA Securities Neutral → Buy
Aug-17-22 Initiated Cowen Market Perform
Jul-13-22 Upgrade SVB Leerink Mkt Perform → Outperform
Jul-06-22 Resumed Canaccord Genuity Buy
Feb-01-22 Upgrade Redburn Sell → Neutral
Dec-16-21 Initiated Morgan Stanley Equal-Weight
Nov-10-21 Upgrade H.C. Wainwright Neutral → Buy
Oct-22-21 Initiated Deutsche Bank Hold
Oct-07-21 Initiated Jefferies Hold
Aug-11-21 Upgrade Bryan Garnier Neutral → Buy
Jul-19-21 Resumed Wolfe Research Outperform
Jun-16-21 Downgrade Redburn Neutral → Sell
May-18-21 Initiated Goldman Neutral
May-11-21 Downgrade Bryan Garnier Buy → Neutral
Dec-01-20 Downgrade BofA Securities Buy → Neutral
Aug-03-20 Resumed Berenberg Buy
Jul-21-20 Upgrade BofA Securities Neutral → Buy
Jun-30-20 Downgrade H.C. Wainwright Buy → Neutral
May-19-20 Upgrade H.C. Wainwright Neutral → Buy
Apr-28-20 Downgrade BofA/Merrill Buy → Neutral
Mar-18-20 Downgrade JP Morgan Overweight → Neutral
Mar-09-20 Initiated H.C. Wainwright Neutral
Jan-24-20 Downgrade SVB Leerink Outperform → Mkt Perform
Jan-22-20 Downgrade UBS Buy → Neutral
Nov-05-19 Initiated Wolfe Research Outperform
Nov-04-19 Initiated Berenberg Buy
Nov-04-19 Initiated BofA/Merrill Buy
Nov-04-19 Initiated Canaccord Genuity Buy
Nov-04-19 Initiated JP Morgan Overweight
Nov-04-19 Initiated SVB Leerink Outperform
Nov-04-19 Initiated UBS Buy
View All

Biontech Se Adr Stock (BNTX) Latest News

pulisher
Sep 23, 2025

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

Sep 23, 2025
pulisher
Sep 23, 2025

JPMorgan Chase & Co. Issues Positive Forecast for BioNTech (NASDAQ:BNTX) Stock Price - Defense World

Sep 23, 2025
pulisher
Sep 23, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Sep 23, 2025
pulisher
Sep 22, 2025

Baader Bank Aktiengesellschaft Acquires 9,040 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat

Sep 22, 2025
pulisher
Sep 21, 2025

37,500 Shares in BioNTech SE Sponsored ADR $BNTX Bought by Swedbank AB - MarketBeat

Sep 21, 2025
pulisher
Sep 21, 2025

Rep. Val T. Hoyle Sells BioNTech SE Sponsored ADR (NASDAQ:BNTX) Shares - MarketBeat

Sep 21, 2025
pulisher
Sep 20, 2025

Lingohr Asset Management GmbH Sells 36,209 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat

Sep 20, 2025
pulisher
Sep 19, 2025

Weekly Market Update: Stocks Gain 1.25%, Led by Technology and Communication Services - Morningstar

Sep 19, 2025
pulisher
Sep 18, 2025

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises - Benzinga

Sep 18, 2025
pulisher
Sep 18, 2025

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises - Ariva

Sep 18, 2025
pulisher
Sep 17, 2025

BioNTech’s New PDAC Study: A Potential Game-Changer in Cancer Treatment? - MSN

Sep 17, 2025
pulisher
Sep 17, 2025

BioNTech (NASDAQ:BNTX) Sees Strong Trading VolumeStill a Buy? - MarketBeat

Sep 17, 2025
pulisher
Sep 15, 2025

Fred Alger Management LLC Sells 403,447 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat

Sep 15, 2025
pulisher
Sep 15, 2025

Millennium Management LLC Increases Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat

Sep 15, 2025

Biontech Se Adr Stock (BNTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$29.45
price up icon 2.51%
$141.00
price down icon 3.01%
$84.16
price down icon 0.45%
$35.77
price down icon 1.30%
biotechnology ONC
$329.84
price up icon 0.23%
Cap:     |  Volume (24h):